Mag Con: Efficacy of Oral Mag. in Acute Concussion in Adolescents

A Randomized Trial Evaluating the Efficacy of Oral Magnesium in Symptomatic Reduction of Acute Concussion in Adolescents

This randomized trial will compare the clinical efficacy of adding oral magnesium oxide to acetaminophen and ondansetron in the treatment of adolescents presenting within 48 hours of a mild traumatic brain injury using the Post-Concussion Symptom Severity Score Index.

This randomized trial will compare the clinical efficacy of oral magnesium oxide, acetaminophen and ondansetron, to that of PO acetaminophen and ondansetron in the treatment of adolescents presenting within 48 hours of a mild traumatic brain injury. Our primary endpoint will be to evaluate if magnesium has an impact on patient's Post-Concussion Symptom Severity Score Index. This will be evaluated both at the initial presentation in-person and then at 24, 48, and 72 hours via phone

Inclusion Criteria:

• age 12 to 18 years;
• presenting chief complaint of headache, head injury, or concussion within the first 48 hours of injury;
• GCS > 13 on arrival

Exclusion Criteria:

• age < 12 years or > 18 years;
• inability to provide informed consent;
• vomiting > 2 episodes following injury;
• physical or mental disability hindering adequate response to assessment of symptoms;
• hemodynamic instability/medical condition requiring further acute life-saving medical intervention;
• known brain mass, intracranial hemorrhage, skull fracture;
• known contraindications/allergy to magnesium, ondansetron, or acetaminophen
• pregnant patients